The well-known oncogenic variant V600E is most prevalent, accounting for approximately 40% of all BRAF mutations and 2% of all patients with NSCLC, followed by G469 and G466 which comprises 22% and 11% of BRAF mutations, respectively4–7. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.